

GUILLERMO RUIZ-IRASTORZA

Grupo de Enfermedades Autoinmunes

1990. Licenciado en Medicina, Universidad Autónoma de Madrid

1999. Doctor en Medicina, UPV/EHU. Premio extraordinario de Doctorado

1996. Especialista en Medicina Interna, HU Cruces

1991-1995. Residente de Medicina Interna, HU Cruces

1994 & 1999-2000. Research Fellow, Lupus Research Unit, St. Thomas' Hospital, UK

1997-2001. Facultativo Especialista en Medicina Interna, Hospital de Mendaró

2001-2010. Facultativo Especialista en Medicina Interna, HU Cruces

Desde 2010. Jefe de Sección de Enfermedades Autoinmunes, HU Cruces

Desde 2004. Profesor Titular de Medicina, UPV/EHU

211 publicaciones indexadas.

Índice h WOS 49

Áreas principales de investigación: lupus eritematoso sistémico, síndrome antifosfolípido, enfermedades autoinmunes y embarazo.

Miembro de SLICC (Systemic Lupus Collaborating Clinics).

Miembro del Grupo de Estudio de Enfermedades Autoinmunes Sistémicas (GEAS).

Coordinador del Área de Enfermedades Autoinmunes, Inflamatorias e Infecciosas del Instituto de Investigación BioCruces Bizkaia.

Jefe del Grupo de Investigación de Enfermedades Autoinmunes, Instituto de Investigación BioCruces Bizkaia.

PUBLICACIONES SELECCIONADAS

Ugarte A, Garcia de Bustos A, Ruiz-Arruza I, Soto-Peleteiro A, Martin-Iglesias D, Gonzalez-Echavarri C, **Ruiz-Irastorza G**. Antiphospholipid antibodies do not predict damage in SLE patients in the XXI century. An observational study from the Lupus-Cruces cohort. *Rheumatology (Oxford)*. 2021 Mar 26:keab307. doi: 10.1093/rheumatology/keab307. Epub ahead of print. PMID: 33769455

Ruiz-Irastorza G, Bertias G. Treating systemic lupus erythematosus in the 21st century: new drugs and new perspectives on old drugs. *Rheumatology (Oxford)*. 2020 Dec 5;59(Suppl5):v69-v81. doi: 10.1093/rheumatology/keaa403. PMID: 33280011; PMCID: PMC7719039.

Ruiz-Irastorza G, Pijoan JI, Bereciartua E, Dunder S, Dominguez J, Garcia-Escudero P, Rodrigo A, Gomez-Carballo C, Varona J, Guio L, Ibarrola M, Ugarte A, Martinez-Berriotxo A; Cruces COVID Study Group. Second week methyl-prednisolone pulses improve prognosis in patients with severe coronavirus disease 2019 pneumonia: An observational comparative study using routine care data. *PLoS One*. 2020 Sep 22;15(9):e0239401. doi: 10.1371/journal.pone.0239401. PMID: 32960899; PMCID: PMC7508405.

Tektonidou MG, Andreoli L, Limper M, Amoura Z, Cervera R, Costedoat-Chalumeau N, Cuadrado MJ, Dörner T, Ferrer-Oliveras R, Hambly K, Khamashta MA, King J, Marchiori F, Meroni PL, Mosca M, Pengo V, Raio L, **Ruiz-Irastorza G**, Shoenfeld Y, Stojanovich L, Svenungsson E, Wahl D, Tincani A, Ward MM. EULAR recommendations for the management of antiphospholipid syndrome in adults. *Ann Rheum Dis*. 2019 May 15. pii: annrheumdis-2019-215213. doi: 10.1136/annrheumdis-2019-215213. [Epub ahead of print] PubMed PMID: 31092409

Aringer M, Costenbader K, Daikh D, Brinks R, Mosca M, Ramsey-Goldman R, Smolen JS, Wofsy D, Boumpas DT, Kamen DL, Jayne D, Cervera R, Costedoat-Chalumeau N, Diamond B, Gladman DD, Hahn B, Hiepe F, Jacobsen S, Khanna D, Lerstrøm K, Massarotti E, McCune J, **Ruiz-Irastorza G**, Sanchez-Guerrero J, Schneider M, Urowitz M, Bertias G, Hoyer BF, Leuchten N, Tani C, Tedeschi SK, Touma Z, Schmajak G, Anic B, Assan F, Chan TM, Clarke AE, Crow MK, Cziráj L, Doria A, Graninger W, Halda-Kiss B, Hasni S, Izmirly PM, Jung M, Kumánovics G, Mariette X, Padjen I, Pego-

Reigosa JM, Romero-Diaz J, Rúa-Figueroa Fernández Í, Seror R, Stummvoll GH, Tanaka Y, Tektonidou MG, Vasconcelos C, Vital EM, Wallace DJ, Yavuz S, Meroni PL, Fritzler MJ, Naden R, Dörner T, Johnson SR. 2019 European League Against Rheumatism/American College of Rheumatology classification criteria for systemic lupus erythematosus. *Ann Rheum Dis*. 2019 Sep;78(9):1151-1159

Ugarte A, Danza A, **Ruiz-Irastorza G**. Glucocorticoids and antimalarials in systemic lupus erythematosus: an update and future directions. *Curr Opin Rheumatol*. 2018 Sep;30(5):482-489.

Uthman I, Noureldine MHA, **Ruiz-Irastorza G**, Khamashta M. Management of antiphospholipid syndrome. *Ann Rheum Dis*. 2018 Oct 3. pii: annrheumdis-2018-213846. doi: 10.1136/annrheumdis-2018-213846. [Epub ahead of print] PubMed PMID: 30282668.

Ruiz-Arruza I, Lozano J, Cabezas-Rodriguez I, Medina JA, Ugarte A, Erdozain JG, **Ruiz-Irastorza G**. A restrictive use of oral glucocorticoids in systemic lupus erythematosus prevents damage without worsening long-term disease control: An observational study. *Arthritis Care Res (Hoboken)*. 2018 Apr;70(4):582-591.

Ruiz-Irastorza G, Ugarte A, Saint-Pastou Terrier C, Lazaro E, Iza A, Couzi L, Saenz R, Richez C, Porta S, Blanco P. Repeated pulses of methyl-prednisolone with reduced doses of prednisone improve the outcome of class III, IV and V lupus nephritis: An observational comparative study of the Lupus-Cruces and Lupus-Bordeaux cohorts. *Autoimmun Rev*. 2017;16:826-832.

Ruiz-Irastorza G, Garcia M, Espinosa G, Caminal L, Mitjavila F, González-León R, Sopeña B, Canora J, Villalba MV, Rodríguez-Carballeira M, López-Dupla JM, Callejas JL, Castro A, Tolosa C, Sánchez-García ME, Pérez-Conesa M, Navarrete-Navarrete N, Rodríguez AP, Herranz MT, Pallarés L. First month prednisone dose predicts prednisone burden during the following 11 months: an observational study from the RELES cohort. *Lupus Sci Med*. 2016 Aug 2;3(1).

Kaul A, Gordon C, Crow MK, Touma Z, Urowitz MB, van Vollenhoven R, **Ruiz-Irastorza G**, Hughes G. Systemic lupus erythematosus. *Nat Rev Dis Primers*. 2016;2:16039.

Götestam Skorpen C, Hoeltzenbein M, Tincani A, Fischer-Betz R, Elefant E, Chambers C, da Silva J, Nelson-Piercy C, Cetin I, Costedoat-Chalumeau N, Dolhain R, Förger F, Khamashta M, **Ruiz-Irastorza G**, Zink A, Vencovsky J, Cutolo M, Caeyers N, Zumbühl C, Østensen M. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. *Ann Rheum Dis.* 2016;75:795-810.

Ruiz-Arruza I, Barbosa C, Ugarte A, **Ruiz-Irastorza G**. Comparison of high versus low-medium prednisone doses for the treatment of systemic lupus erythematosus patients with high activity at diagnosis. *Autoimmun Rev.* 2015;14:875-9.

Ruiz-Arruza I, Ugarte A, Cabezas-Rodriguez I, Medina JA, Moran MA, **Ruiz-Irastorza G**. Glucocorticoids and irreversible damage in patients with systemic lupus erythematosus. *Rheumatology (Oxford).* 2014;53:1470-6.

Bruce IN, O'Keeffe AG, Farewell V, Hanly JG, Manzi S, Su L, Gladman DD, Bae SC, Sanchez Guerrero J, Romero-Diaz J, Gordon C, Wallace DJ, Clarke AE, Bernatsky S, Ginzler EM, Isenberg DA, Rahman A, Merrill JT, Alarcón GS, Fessler BJ, Fortin PR, Petri M, Steinsson K, Dooley MA, Khamashta MA, Ramsey-Goldman R, Zoma AA, Sturfelt GK, Nived O, Aranow C, Mackay M, Ramos-Casals M, van Vollenhoven RF, Kalunian KC, **Ruiz-Irastorza G**, Lim S, Kamen DL, Peschken CA, Inanc M, Urowitz MB. Factors associated with damage accrual in patients with systemic lupus erythematosus: results from the Systemic Lupus International Collaborating Clinics (SLICC) Inception Cohort. *Ann Rheum Dis.* 2015;74:1706-13

Ruiz-Irastorza G, Danza A, Perales I, Villar I, Garcia M, Delgado S, Khamashta M. Prednisone in lupus nephritis: how much is enough? *Autoimmun Rev.* 2014;13:206-14.

Petri M, Orbai AM, Alarcón GS, Gordon C, Merrill JT, Fortin PR, Bruce IN, Isenberg D, Wallace DJ, Nived O, Sturfelt G, Ramsey-Goldman R, Bae SC, Hanly JG, Sanchez-Guerrero J, Clarke A, Aranow C, Manzi S, Urowitz M, Gladman D, Kalunian K, Costner M, Werth VP, Zoma A, Bernatsky S, **Ruiz-Irastorza G**, Khamashta MA, Jacobsen S, Buyon JP, Maddison P, Dooley MA, Vollenhoven RF, Ginzler E, Stoll T, Peschken C, Jorizzo JL, Callen JP, Lim SS, Fessler BJ, Inanc M, Kamen DL, Rahman A, Steinsson K, Franks AG Jr, Sigler L, Hameed S, Fang H, Pham N, Brey R, Weisman MH, McGwin G Jr, Magder LS. Derivation and validation of systemic lupus international collaborating clinics. Classification criteria for systemic lupus erythematosus. *Arthritis Rheum.* 2012;64:2677-86.

Ruiz-Irastorza G, Espinosa G, Frutos MA, Jimenez Alonso J, Praga M, Pallares L, Rivera F, Robles Marhuenda A, Segarra A, Quereda C. Diagnóstico y tratamiento de la nefritis lúpica. Documento de consenso del Grupo de Enfermedades Autoinmunes Sistémicas (GEAS) de la Sociedad Española de Medicina Interna (SEMI) y de la Sociedad Española de Nefrología (SEN). *Rev Clin Esp.* 2012; 212:147

Ruiz-Irastorza G, Cuadrado MJ, Ruiz-Arruza I, Brey R, Crowther M, Derksen R, Erkan D, Krilis S, Machin S, Pengo V, Pierangeli S, Tektonidou M, Khamashta M. Evidence-based recommendations for the prevention and long-term management of thrombosis in antiphospholipid antibody-positive patients: report of a task force at the 13th International Congress on antiphospholipid antibodies. *Lupus.* 2011;20:206-18.

Ruiz-Irastorza G, Crowther MA, Branch DW, Khamashta MA. Antiphospholipid syndrome. *Lancet* 2010;376:1498-509

Ruiz-Irastorza G, Gordo S, Olivares N, Egurbide MV, Aguirre C. Changes in vitamin D levels in patients with systemic lupus erythematosus: Effects on fatigue, disease activity and damage. *Arthritis Care Res (Hoboken).* 2010;62:1160-5

Ruiz-Irastorza G, Ramos-Casals M, Brito-Zeron P, Khamashta MA. Clinical efficacy and side effects of antimalarials in systemic lupus erythematosus: a systematic review. *Ann Rheum Dis.* 2010;69:20-8.

Ruiz-Irastorza G, Olivares N, Ruiz-Arruza I, Martinez-Berriotxo A, Egurbide MV, Aguirre C. Predictors of major infections in systemic lupus erythematosus. *Arthritis Res Ther.* 2009;11:R109.

Ruiz-Irastorza G, Egurbide MV, Pijoan JI, Garmendia M, Villar I, Martinez-Berriotxo A, Erdozain JG, Aguirre C. Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. *Lupus.* 2006;15:577-83.